Insider

Regeneron Pharmaceuticals, Inc.

REGN Health Care · 5 analyses · 6 expectations tracked

Regeneron Pharmaceuticals reported $5.1B in revenue (+36.3% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 6 open management expectations for this company. 9 insider sales recorded. Its latest periodic filing added 4 new risk factors. Next scheduled event: Dividend on December 3, 2026.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

Deals & ownership

Regeneron Pharmaceuticals insider transactions

Between November 2 and November 4, 2026, executives and directors of Regeneron Pharmaceuticals, Inc. filed reports detailing completed trades and proposed future stock sales. These filings reflect insider activity involving stock option exercises and the subsequent disposal of securities.

Upcoming events

As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →

Company history

October 2026

REGENERON PHARMACEUTICALS, INC.: 12 recorded developments from 1 official source in 2026-10.

  • 2026-10-30: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-07-01 to 2026-09-30: 5,115,800,000 USD (5.1 billion; 5,116 million); same period a year earlier (2025-07-01 to 2025-09-30): 3,754,300,000 USD (3.8 billion; 3,754 million); change +36.3% Source
  • 2026-10-30: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2026-01-01 to 2026-09-30: 13,011,900,000 USD (13 billion; 13,012 million); same period a year earlier (2025-01-01 to 2025-09-30): 10,458,600,000 USD (10.5 billion; 10,459 million); change +24.4% Source
  • 2026-10-30: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 2,048,200,000 USD (2 billion; 2,048 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,026,800,000 USD (1 billion; 1,027 million); change +99.5% Source
  • 2026-10-30: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 3,984,600,000 USD (4 billion; 3,985 million); same period a year earlier (2025-01-01 to 2025-09-30): 2,698,000,000 USD (2.7 billion; 2,698 million); change +47.7% Source
  • 2026-10-30: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 1,948,700,000 USD (1.9 billion; 1,949 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,460,000,000 USD (1.5 billion; 1,460 million); change +33.5% Source
  • 2026-10-30: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 3,972,800,000 USD (4 billion; 3,973 million); same period a year earlier (2025-01-01 to 2025-09-30): 3,660,300,000 USD (3.7 billion; 3,660 million); change +8.5% Source
  • 2026-10-30: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-07-01 to 2026-09-30: 1,794,700,000 USD (1.8 billion; 1,795 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,475,000,000 USD (1.5 billion; 1,475 million); change +21.7% Source
  • 2026-10-30: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), year to date 2026-01-01 to 2026-09-30: 4,969,800,000 USD (5 billion; 4,970 million); same period a year earlier (2025-01-01 to 2025-09-30): 4,224,100,000 USD (4.2 billion; 4,224 million); change +17.7% Source
  • 2026-10-30: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 3,675,300,000 USD (3.7 billion; 3,675 million); same period a year earlier (2025-01-01 to 2025-09-30): 3,808,200,000 USD (3.8 billion; 3,808 million); change -3.5% Source
  • 2026-10-30: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 3,659,100,000 USD (3.7 billion; 3,659 million); previous balance (2025-12-31): 3,118,100,000 USD (3.1 billion; 3,118 million); change +17.4% Source
  • 2026-10-30: Total liabilities (us-gaap:Liabilities), as of 2026-09-30: 10,906,700,000 USD (10.9 billion; 10,907 million); previous balance (2025-12-31): 9,301,800,000 USD (9.3 billion; 9,302 million); change +17.3% Source
  • 2026-10-30: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 33,498,500,000 USD (33.5 billion; 33,499 million); previous balance (2025-12-31): 31,256,900,000 USD (31.3 billion; 31,257 million); change +7.2% Source

September 2026

REGENERON PHARMACEUTICALS, INC.: 2 recorded developments from 1 official source in 2026-09.

  • REGENERON PHARMACEUTICALS INC contract modification P00018 action date was 2026-09-25 Source
  • 2026-09-25: Department of Health and Human Services awarded contract to REGENERON PHARMACEUTICALS INC Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 30, 2026. SEC

LatestEarlierChange
Revenue quarter$5.1B$3.8B+36.3%
Operating income quarter$2B$1B+99.5%
Net income quarter$1.9B$1.5B+33.5%
Diluted EPS quarter$18.45$13.62+35.5%
Dividends per share quarter$0.94——
Operating cash flow year to date$3.7B$3.8B-3.5%
Cash and cash equivalents balance$3.7B$3.1B+17.4%
Long-term debt balance$2B$2B+0.1%

Next results expected around January 29, 2027 (estimate: the quarter ending about December 30, 2026 plus the 30 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

3.8Q4 '24*26.1%3Q1 '2519.5%3.7Q2 '2529.4%3.8Q3 '2527.3%3.9Q4 '25*22.7%3.6Q1 '2617.8%4.3Q2 '2630.1%5.1Q3 '2640%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Regeneron Pharmaceuticals, Inc. REGN$5.1B+36.3%40.0%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • The Company plans to initiate a Phase 3 study in POTS in the first half of 2027, pending regulatory feedback.

    Said October 30, 2026 · Period named: first half of 2027 · Source · Our article

    Not yet checked against later reports.

  • The company has a supplemental Biologics License Application for Libtayo under review by the FDA with a target action date in March 2027.

    Said October 30, 2026 · Period named: March 2027 · Source · Our article

    Not yet checked against later reports.

  • The Company expects to deliver a pre-specified number of treatment doses of Inmazeb each year to the U.S. government beginning in 2027 through 2031.

    Said October 30, 2026 · Period named: 2027 through 2031 · Source · Our article

    Not yet checked against later reports.

  • The Company plans to initiate a Phase 3 study in metabolic dysfunction-associated steatohepatitis (MASH)/MASLD in the fourth quarter of 2026.

    Said October 30, 2026 · Period named: fourth quarter of 2026 · Source · Our article

    Not yet checked against later reports.

  • The FDA target action date for the Ordspono (odronextamab) BLA resubmission is in February 2027.

    Said October 30, 2026 · Period named: February 2027 · Source · Our article

    Not yet checked against later reports.

  • The Company plans to present interim results from its RNAi therapy study for metabolic dysfunction-associated steatotic liver disease (MASLD) at the AASLD Meeting in November 2026.

    Said October 30, 2026 · Period named: November 2026 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Changes in risk factors

The 10-Q filed October 30, 2026 compared with the 10-Q filed July 30, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC

Added (4)

  • the United States, we continue to rely in considerable part on Sanofi's sales and marketing organization in such jurisdictions. Sanofi also leads or will lead the commercialization efforts for the other products and product candidates subject to the Antibody Collaboration, which now includes four new product candidates pursuant to the recent amendment to the Antibody Collaboration discussed under Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations – Collaboration, License, and Other Agreements – Sanofi."
  • In particular, our business activities outside the United States (which have recently expanded and continue to expand due to, in part, our efforts to establish further commercialization capabilities in certain jurisdictions outside the United States) are subject
  • imports from all trading partners under Section 122 of the Trade Act of 1974 ("Section 122"). This surcharge expired on July 24, 2026.

Dropped (6)

  • provisions of the agreement governing the Antibody Collaboration (the "Collaboration Agreement"). These provisions concern Sanofi's obligation to provide Regeneron with full access to material information relating to the commercialization of Dupixent or other products commercialized pursuant to the Collaboration Agreement and Regeneron's audit rights under the Collaboration Agreement. It is not possible to determine what impact (if any) the Antibody Collaboration Litigation may have on the Antibody Collaboration and our business relationship with Sanofi, or whether we will be successful in…
  • The federal civil False Claims Act prohibits any person from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement
  • Civil monetary penalties can be applied if we fail to pay the required rebate, if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our

Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
September 30, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 17, 2026Murphy Andrew JPlanned sale 10b5-1 plan5,011—$4,773,278SEC
November 17, 2026George L. SingPlanned sale1,000—$957,687SEC
November 16, 2026George L. SingPlanned sale1,000—$960,264SEC
November 16, 2026McCourt MarionPlanned sale 10b5-1 plan566—$545,239SEC
November 4, 2026Jason PitofskySale4,062$942.19$3,827,159SEC
November 4, 2026Jason PitofskyPlanned sale3,883—$3,789,808SEC
November 3, 2026Huda Y ZoghbiSale notice filed7,439$970.46$7,219,274SEC
November 2, 2026George L SingSale notice filed21,129$964.38$20,376,358SEC
November 2, 2026Christine A PoonSale7,830$969.09$7,587,958SEC
November 2, 2026Joseph J LarosaSale notice filed4,466$965.49$4,311,890SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock8,849,583$6,710,372,953-2.9%Q3 2026
State Street4,881,362$3,701,390,364+1.0%Q3 2026
Geode Capital Management2,632,826$1,992,068,413+0.3%Q3 2026
Wellington Management1,271,957$964,486,836+0.1%Q3 2026
Fidelity (FMR)1,035,204$784,964,318+24.4%Q3 2026
Norges Bank (Norway's sovereign fund)1,172,808$731,292,700—Q2 2026
Two Sigma Investments869,505$659,319,556+32.5%Q3 2026
Citadel Advisors352,728$267,463,060+512.3%Q3 2026
Renaissance Technologies272,218$206,414,743+83.7%Q3 2026
Millennium Management147,538$111,873,639-10.6%Q3 2026
Bridgewater Associates105,934$80,326,574+106.4%Q3 2026
Capital Research Global Investors101,891$78,724,785—Q1 2026
D. E. Shaw & Co.58,636$44,461,919+52.4%Q3 2026
T. Rowe Price1,103,865$837,028-27.8%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.